KR102586747B1 - 캡슐 제형 - Google Patents
캡슐 제형 Download PDFInfo
- Publication number
- KR102586747B1 KR102586747B1 KR1020217019883A KR20217019883A KR102586747B1 KR 102586747 B1 KR102586747 B1 KR 102586747B1 KR 1020217019883 A KR1020217019883 A KR 1020217019883A KR 20217019883 A KR20217019883 A KR 20217019883A KR 102586747 B1 KR102586747 B1 KR 102586747B1
- Authority
- KR
- South Korea
- Prior art keywords
- solid solution
- peg
- solution capsule
- compound
- nonionic surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| US62/773,848 | 2018-11-30 | ||
| PCT/US2019/063547 WO2020112961A1 (en) | 2018-11-30 | 2019-11-27 | Capsule formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210098489A KR20210098489A (ko) | 2021-08-10 |
| KR102586747B1 true KR102586747B1 (ko) | 2023-10-06 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217019883A Active KR102586747B1 (ko) | 2018-11-30 | 2019-11-27 | 캡슐 제형 |
Country Status (31)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| CN116635075A (zh) * | 2020-12-21 | 2023-08-22 | 坎莫森特里克斯公司 | 使用c5a抑制剂治疗c3肾小球病 |
| JP2025516701A (ja) * | 2022-05-19 | 2025-05-30 | ダウ グローバル テクノロジーズ エルエルシー | Bcsクラスiiの薬物の改良された可溶化のためのpegベースのインターポリマー錯体の使用 |
| US20250164505A1 (en) * | 2023-11-20 | 2025-05-22 | Qatar Foundation For Education, Science And Community Development | Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder |
| WO2025203055A1 (en) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180179160A1 (en) | 2010-06-24 | 2018-06-28 | Chemocentryx, Inc. | C5ar antagonists |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| AU2005309808A1 (en) * | 2004-11-24 | 2006-06-01 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| MX363066B (es) * | 2007-05-29 | 2019-03-07 | Intrexon Corp | Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona. |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110312973A1 (en) | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| EP2659090B1 (en) | 2010-12-27 | 2017-08-23 | Seven Generations Energy Ltd. | Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources |
| CN106102716A (zh) | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| SG11201805828YA (en) | 2016-01-14 | 2018-08-30 | Chemocentryx Inc | Method of treating c3 glomerulopathy |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| DK3411400T3 (da) | 2017-04-03 | 2021-10-11 | Inflarx Gmbh | Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet |
| CN111741754A (zh) | 2017-10-30 | 2020-10-02 | 凯莫森特里克斯股份有限公司 | 作为免疫调节剂的氘代化合物 |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス,インコーポレイティド | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
-
2019
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en not_active Ceased
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/en active Pending
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 CA CA3120999A patent/CA3120999C/en active Active
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/en active Active
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-06-03 ZA ZA2021/03820A patent/ZA202103820B/en unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180179160A1 (en) | 2010-06-24 | 2018-06-28 | Chemocentryx, Inc. | C5ar antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11951214B2 (en) | Capsule formulations | |
| CN103635179B (zh) | 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法 | |
| CN102281871A (zh) | 苯达莫司汀的口服剂型 | |
| TWI500431B (zh) | 苯達莫司汀(bendamustine)的口服劑量型 | |
| RU2824998C2 (ru) | Лекарственные формы в виде капсул | |
| RU2824998C9 (ru) | Лекарственные формы в виде капсул | |
| HK40121602A (en) | Capsule formulations | |
| HK40098440B (en) | Capsule formulations | |
| HK40098440A (en) | Capsule formulations | |
| HK40060732A (en) | Capsule formulations | |
| HK40060732B (en) | Capsule formulations | |
| EP4203919A1 (en) | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists | |
| HK1179865A (en) | Oral dosage forms of bendamustine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210625 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20221118 Comment text: Request for Examination of Application |
|
| A302 | Request for accelerated examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20230306 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230327 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230703 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231004 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231004 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |